<DOC>
	<DOCNO>NCT01245530</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety two fix dose ( 1200mg/day , 1600mg/day ) INM-176 ( drug treat dementia ) compare donepezil treatment patient Alzheimer type dementia .</brief_summary>
	<brief_title>An Efficacy Safety Study INM-176 Treatment Patients With Alzheimer Type Dementia</brief_title>
	<detailed_description>Probable Alzheimer type dementia compare INM-176 1200~1600mg/day Donepezil 5~10mg/day safety efficacy randomization , multicenter , double-blind , double-dummy , parallel Phase III clinical study .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Male female , age range : 50 ~ 80 year old 2 . Informed consent sign date patient legal representative 3 . Subjects diagnose Alzheimer 's disease accord DSMIV criterion 4 . Subjects diagnose probable Alzheimer 's disease accord National Institute Neurological Communicative Disorders Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criteria 5 . MMSE score 10 26 6 . CDR ( Clinical Dementia Rating ) score 1~2 GDS ( Global Deterioration Scale ) 3~5 stage 7 . Subjects n't take medication AchEI ( donepezil , memantine , galantamin , etc ) treat stop medication least 4 week prior screen visit 8 . Subjects menopause woman her/his spouse consent contraception study period 90 day end study 1 . Subjects psychiatric disorder Alzheimer 's disease , schizophrenia , depression , bipolar disorder , etc 2 . Subjects diagnose accompanied Dementia due Neurodegenerative disorder ( AIDS , syphilis , creutzfeldtjacob disease , Picks Disease , Huntingtons Disease , Parkinsons disease related dementia ) 3 . Subjects diagnose vascular dementia 4 . Subjects diagnose stroke within last 3 month prior screen visit 5 . Subjects medical history significant hepatic disease screen visit ( 2 ULN≤ALT , AST ) 6 . Subjects medical history significant renal disease screen visit ( 1.5mg/dl≤Serum creatinine ) 7 . Subjects difficult regulate blood glucose level antidiabetes drug ( 8.0 % &lt; HbA1c ) 8 . Subjects medical history myocardial infarction arrhythmia 9 . Subjects take warfarin Atrial fibrillation 10 . Pregnant nursing woman 11 . Subjects p0articipated clinical trail within last 3 month 12 . Subjects hypersensitivity AchEl ( acetylcholinesterase inhibitor ) 13 . Subjects unstable clinical laboratory result screen visit 14 . Subjects doubt pulmonary disease chest Xray screen visit 15 . Subjects consider unsuitable participate clinical trail investigator</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Alzheimer disease</keyword>
</DOC>